Lingling Dai

Lingling Dai is an Associate Principal Scientist at AstraZeneca, bringing over 15 years of drug discovery experience, particularly in cancer biology and targeted therapies. With expertise in PROTAC technology and immunology, they have led innovative projects that transitioned first-in-class anti-cancer small molecules to the clinic. Lingling previously held research fellowships at prestigious institutions such as Harvard T.H. Chan School of Public Health and Dana-Farber Cancer Institute, where they established high-throughput screening platforms and led pivotal clinical trials. Their contributions to the field have been recognized with multiple publications and the AstraZeneca Top 5% Outstanding Performance Award for two consecutive years.